🎉 M&A multiples are live!
Check it out!

Celltrion Pharm Valuation Multiples

Discover revenue and EBITDA valuation multiples for Celltrion Pharm and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Celltrion Pharm Overview

About Celltrion Pharm

Celltrion Pharm Inc is active in the Korean healthcare sector. Its core business includes the manufacture and sale of pharmaceuticals such as heptatonic, analgesics, antipyretics, anti-inflammatory drugs, antihistamines, respiratory apparatus drugs and antibiotics.


Founded

1976

HQ

South Korea
Employees

n/a

Website

celltrionph.com

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$1.5B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Celltrion Pharm Financials

Celltrion Pharm has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Celltrion Pharm achieved revenue of $326M and an EBITDA of $39.1M.

Celltrion Pharm expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Celltrion Pharm valuation multiples based on analyst estimates

Celltrion Pharm P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $265M $326M XXX XXX XXX
Gross Profit $76.8M $81.6M XXX XXX XXX
Gross Margin 29% 25% XXX XXX XXX
EBITDA $36.9M $39.1M XXX XXX XXX
EBITDA Margin 14% 12% XXX XXX XXX
Net Profit $17.7M $14.5M XXX XXX XXX
Net Margin 7% 4% XXX XXX XXX
Net Debt $87.8M $94.3M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Celltrion Pharm Stock Performance

As of April 15, 2025, Celltrion Pharm's stock price is KRW 48100 (or $33).

Celltrion Pharm has current market cap of KRW 2.09T (or $1.4B), and EV of KRW 2.19T (or $1.5B).

See Celltrion Pharm trading valuation data

Celltrion Pharm Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$1.5B $1.4B XXX XXX XXX XXX n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Celltrion Pharm Valuation Multiples

As of April 15, 2025, Celltrion Pharm has market cap of $1.4B and EV of $1.5B.

Celltrion Pharm's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Celltrion Pharm's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Celltrion Pharm and 10K+ public comps

Celltrion Pharm Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $1.5B XXX XXX XXX
EV/Revenue 4.6x XXX XXX XXX
EV/EBITDA 38.2x XXX XXX XXX
P/E 95.2x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 43.3x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Celltrion Pharm Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Celltrion Pharm Valuation Multiples

Celltrion Pharm's NTM/LTM revenue growth is n/a

Celltrion Pharm's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.

Over next 12 months, Celltrion Pharm's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Celltrion Pharm's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Celltrion Pharm and other 10K+ public comps

Celltrion Pharm Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 23% XXX XXX XXX XXX
EBITDA Margin 12% XXX XXX XXX XXX
EBITDA Growth 6% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee n/a XXX XXX XXX XXX
S&M Expenses to Revenue 5% XXX XXX XXX XXX
G&A Expenses to Revenue 1% XXX XXX XXX XXX
R&D Expenses to Revenue 3% XXX XXX XXX XXX
Opex to Revenue 18% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Celltrion Pharm Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Celltrion Pharm M&A and Investment Activity

Celltrion Pharm acquired  XXX companies to date.

Last acquisition by Celltrion Pharm was  XXXXXXXX, XXXXX XXXXX XXXXXX . Celltrion Pharm acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Celltrion Pharm

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Celltrion Pharm

When was Celltrion Pharm founded? Celltrion Pharm was founded in 1976.
Where is Celltrion Pharm headquartered? Celltrion Pharm is headquartered in South Korea.
Who is the CEO of Celltrion Pharm? Celltrion Pharm's CEO is Mr. Jung-su Seo.
Is Celltrion Pharm publicy listed? Yes, Celltrion Pharm is a public company listed on KRX.
What is the stock symbol of Celltrion Pharm? Celltrion Pharm trades under 068760 ticker.
When did Celltrion Pharm go public? Celltrion Pharm went public in 2006.
Who are competitors of Celltrion Pharm? Similar companies to Celltrion Pharm include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Celltrion Pharm? Celltrion Pharm's current market cap is $1.4B
What is the current revenue growth of Celltrion Pharm? Celltrion Pharm revenue growth between 2023 and 2024 was 23%.
Is Celltrion Pharm profitable? Yes, Celltrion Pharm is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.